Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
A 52-year-old Man with Diplopia and Ataxia
Neurol 87:e140-e143, Bradshaw, M.J.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Efficacy of Treatment of MS with IFN B-1b or Glatiramer Acetate by Monthly Brain MRI in the BECOME Study
Neurol 72:1976-1983,1972, Cadavid,D.,et al, 2009
Real-Life Impact of Early Interferon� Therapy in Relapsing Multiple Sclerosis
Ann Neurol 66:513-520, Trojano,M.,et al, 2009
The Present Efficacy of Multiple Sclerosis Therapeutics
Neurol 73:984-990, Klawiter,E.,et al, 2009
Aicardi-Gouti�res Syndrome: Neuroradiologic Findings and Follow-up
AJNR 30:1971-1976, Uggetti,C.,et al, 2009
Aicardi-Gouti�res Syndrome
Br Med Bull 89:183-201, Orcesi, S.,et al, 2009
Interferon �-Associated Retinopathy in Patients Treated for Multiple Sclerosis
Neurol 70:1153-1155, Folden,D.V.,et al, 2008
Clinicopath Conf., Endheim-Chester Disease
NEJM 359:736-747, Case 25-2008, 2008
Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Effect of Early Verus Delayed Interferon Beta-1b Treatment on Disability After a First Clinical Event Suggestive of Multiple Sclerosis: A 3-Year Follow-Up Analysis of the BENEFIT Study
Lancet 370:389-397, Kappos,L.,et al, 2007
Mangnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results
Arch Neurol 64:1292-1298, Barkhof,F.,et al, 2007
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 69:1552-1553, Sorenson,P.S. &Bertolotto,A., 2007
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005
Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005
Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Pregnancy Outcomes During Treatment with Interferon Beta-1a in Patients with Multiple Sclerosis
Neurol 65:802-806, Sandberg-Wollheim,M.,et al, 2005
The Reproductive Effects of Beta Interferon Therapy in Pregnancy, A longitudinal Cohort
Neurol 65:807-811,788, Boskovic,R.,et al, 2005
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
Clinical Implications of Benign Multiple Sclerosis: A 20-Year Population-Based Follow-Up Study
Ann Neurol 56:303-306, Pittock,S.J.,et al, 2004
Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004
Validation of Diagnositc Magnetic Resonance Imaging Criteria for Multiple Sclerosis and Response to Interferon B1a
Ann Neurol 53:718-724, Barkhof,F.,et al, 2003